Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727304 | 0.87 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTGAAKMT2A | |
| SCHEMBL6724373 | 0.86 | MMP13 (0.46) | ALDH1A1HPGDMAPTGAAKMT2A | |
| SCHEMBL7231592 | 0.85 | MMP2 (0.52) | ALDH1A1HPGDMAPTGAAKMT2A | |
| SCHEMBL6722972 | 0.84 | MMP13 (0.48) | GAALMNA | |
| SCHEMBL6731167 | 0.83 | MMP13 (0.58) | ALDH1A1POLBL3MBTL1LMNA | |
| SCHEMBL6324181 | 0.76 | MMP13 (0.47) | — | |
| SCHEMBL6326727 | 0.76 | MMP13 (0.46) | MAPT | |
| SCHEMBL6325359 | 0.76 | MMP13 (0.46) | — | |
| SCHEMBL6731518 | 0.75 | ADAM17 (0.55) | — | |
| SCHEMBL6322842 | 0.75 | MMP13 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024001-A1 | Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-05 | — | — | US | disclosed |
| WO-2003091252-A1 | SPIROBARBITURIC ACID DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024001-A1 | Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases | MMP13, MMP3, MMP1 | ALDH1A1 374/4885HPGD 1260/4885POLB 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.